PURPOSE: To explore the mechanism of lymphatic access of the CETP inhibitors (CETPi) CP524,515 and CP532,623 and probe their potential effect on lymph lipoprotein development. METHODS: Lymphatic access mechanisms were examined via correlation of lymphatic drug transport profiles with drug affinity for lymph lipoproteins and drug solubility in representative combinations of lipoprotein lipids. The effects of the CETPi on lymph lipoprotein profiles were evaluated by ultracentrifugation and flow cytometry. RESULTS: Both CETPi were highly lymphatically transported (22-28% of dose), and lymphatic transport was closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly related to solubility in mixtures of lipoprotein core and/or surface lipids. Both CETPi altered the kinetics of lymph lipid transport and decreased lymph lipid transport in chylomicrons. CONCLUSION: Lymphatic transport of the CETPi appears to reflect high affinity for the interface of lymph lipoproteins rather than solubilisation in the lipoprotein core and confirms that triglyceride solubilities >50 mg/g are not necessarily a pre-requisite for lymphatic transport. The CETPi also led to changes to lipoprotein processing in the enterocyte including a reduction in lipid transport in chylomicrons. Changes to intestinal lipoprotein profiles may contribute to the changes in systemic lipoprotein levels seen during CETPi therapy.
PURPOSE: To explore the mechanism of lymphatic access of the CETP inhibitors (CETPi) CP524,515 and CP532,623 and probe their potential effect on lymph lipoprotein development. METHODS: Lymphatic access mechanisms were examined via correlation of lymphatic drug transport profiles with drug affinity for lymph lipoproteins and drug solubility in representative combinations of lipoprotein lipids. The effects of the CETPi on lymph lipoprotein profiles were evaluated by ultracentrifugation and flow cytometry. RESULTS: Both CETPi were highly lymphatically transported (22-28% of dose), and lymphatic transport was closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly related to solubility in mixtures of lipoprotein core and/or surface lipids. Both CETPi altered the kinetics of lymph lipid transport and decreased lymph lipid transport in chylomicrons. CONCLUSION: Lymphatic transport of the CETPi appears to reflect high affinity for the interface of lymph lipoproteins rather than solubilisation in the lipoprotein core and confirms that triglyceride solubilities >50 mg/g are not necessarily a pre-requisite for lymphatic transport. The CETPi also led to changes to lipoprotein processing in the enterocyte including a reduction in lipid transport in chylomicrons. Changes to intestinal lipoprotein profiles may contribute to the changes in systemic lipoprotein levels seen during CETPi therapy.
Authors: Natalie L Trevaskis; Claire L McEvoy; Michelle P McIntosh; Glenn A Edwards; Ravi M Shanker; William N Charman; Christopher J H Porter Journal: Pharm Res Date: 2010-03-11 Impact factor: 4.200
Authors: Xiayang Qiu; Anil Mistry; Mark J Ammirati; Boris A Chrunyk; Ronald W Clark; Yang Cong; Jeffrey S Culp; Dennis E Danley; Thomas B Freeman; Kieran F Geoghegan; Matthew C Griffor; Steven J Hawrylik; Cheryl M Hayward; Preston Hensley; Lise R Hoth; George A Karam; Maruja E Lira; David B Lloyd; Katherine M McGrath; Kim J Stutzman-Engwall; Ann K Subashi; Timothy A Subashi; John F Thompson; Ing-Kae Wang; Honglei Zhao; Andrew P Seddon Journal: Nat Struct Mol Biol Date: 2007-01-21 Impact factor: 15.369
Authors: Maryse Guerin; Wilfried Le Goff; Emilie Duchene; Zélie Julia; Tu Nguyen; Tom Thuren; Charles L Shear; M John Chapman Journal: Arterioscler Thromb Vasc Biol Date: 2007-10-19 Impact factor: 8.311
Authors: Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter Journal: Pharm Res Date: 2013-02-21 Impact factor: 4.200
Authors: Margaret R Diffenderfer; Margaret E Brousseau; John S Millar; P Hugh R Barrett; Chorthip Nartsupha; Peter M Schaefer; Megan L Wolfe; Gregory G Dolnikowski; Daniel J Rader; Ernst J Schaefer Journal: J Lipid Res Date: 2012-04-02 Impact factor: 5.922
Authors: Sifei Han; Luojuan Hu; Tim Quach; Jamie S Simpson; Natalie L Trevaskis; Christopher J H Porter Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: Brian D Ross; Youngsoon Jang; Amanda Welton; Christopher A Bonham; Dilrukshika S W Palagama; Kevin Heist; Jagadish Boppisetti; Kasun P Imaduwage; Tanner Robison; Leah R King; Edward Z Zhang; Cyrus Amirfazli; Kathryn E Luker; Winston Y Lee; Gary D Luker; Thomas L Chenevert; Marcian E Van Dort Journal: Nat Commun Date: 2022-08-17 Impact factor: 17.694